Humacyte, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Humacyte, Inc. (HUMA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-27
- Humacyte, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 0.10%.
- Humacyte, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -4.50%.
- Humacyte, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -1.60%, a 101.22% decline from fiscal 2022.
- Humacyte, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was 131.50%, a 190.29% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | 0.10% 10-K · filed 2026-03-27 |
| 2024-12-31 | -4.50% 10-K · filed 2026-03-27 |
| 2023-12-31 | -1.60% 10-K · filed 2025-03-31 |
| 2022-12-31 | 131.50% 10-K · filed 2024-03-28 |
| 2021-12-31 | 45.30% 10-K · filed 2023-03-24 |
| 2020-12-31 | -0.10% 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |